Inhibition of the effector phase of IgE-mediated allergies by tolerogenic conjugates of allergens and monomethoxypolyethylene glycol

Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):316-8. doi: 10.1159/000237012.

Abstract

In this study we established that the conjugate of ovalbumin (OVA), which was used as a model allergen, with monomethoxypolyethylene glycol (mPEG), i.e., OVA(mPEG)11, was not only tolerogenic and essentially non-allergenic, but also capable of inactivating mast cells sensitized with anti-OVA IgE antibodies (Abs). Moreover, mast cells sensitized with a mixture of anti-OVA and anti-DNP IgE Abs were also desensitized by OVA(mPEG)11 with respect to both sensitivities. Most importantly, treatment of OVA-sensitive mice by OVA(mPEG)11 protected them from systemic anaphylaxis on challenge with OVA. The possibility of inactivating IgE-sensitized mast cells with mPEG conjugates of single epitopes of a given allergen is being investigated.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Allergens / adverse effects
  • Allergens / immunology
  • Allergens / therapeutic use*
  • Animals
  • Cattle
  • Desensitization, Immunologic / methods*
  • Dinitrobenzenes / immunology
  • Immunization
  • Immunoglobulin E / immunology*
  • Mast Cells / immunology
  • Mast Cells / metabolism
  • Mice
  • Ovalbumin / adverse effects
  • Ovalbumin / immunology
  • Ovalbumin / therapeutic use
  • Passive Cutaneous Anaphylaxis
  • Polyethylene Glycols / administration & dosage*
  • Rats
  • Rats, Sprague-Dawley
  • Serotonin / metabolism
  • Serum Albumin, Bovine / immunology

Substances

  • Allergens
  • Dinitrobenzenes
  • Serum Albumin, Bovine
  • Serotonin
  • Immunoglobulin E
  • Polyethylene Glycols
  • monomethoxypolyethylene glycol
  • Ovalbumin